Illumina received more orders than expected for NovaSeq in Q2 and sees a big opportunity in the consumer genomics market for its array business and Helix.
Parent firm Gene by Gene calls the law "brief and vague" and is pushing for ancestry testing to be exempt from the provision of the genetic privacy statute.
Among the initial crop of products there may not be a killer app yet, but these first offerings will enable Helix and partners to begin to understand their customer base.
With choice, real-time interpretation, low pricing, and education, Helix believes it may have cracked the formula for integrating genomics into people's daily lives.
NantOmics hopes to enhance its diagnostics platform with the addition of Genos' sequencing technology and expertise.
With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
Launching a diverse product pipeline will also test Helix's ability to manage the challenges of providing genomics interpretations to a broad consumer audience.
The consumer genomics firm Helix will use an FDA-cleared device from OraSure's subsidiary DNA Genotek for collecting DNA samples from customers.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The company has decided to put its direct-to-consumer sequencing campaign on hold after receiving a letter from the FDA.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.